February 2021 Vol 7 No 1

In February 2021, the FDA approved Tepmetko (tepotinib), a new oral targeted therapy, for the treatment of all adults with metastatic non–small-cell lung cancer and MET exon 14 alterations. Tepmetko is the second MET inhibitor that has been approved by the FDA. Read More ›

In December 2020, the FDA approved Tagrisso (osimertinib) for adjuvant therapy (continued therapy to prevent cancer recurrence) after surgical removal of the tumor, in patients with non–small-cell lung cancer and EGFR exon 19 deletions or exon 21 L858R mutations. Tagrisso was previously approved for the treatment of other types of lung cancer. Read More ›

In December 2020, the FDA approved Orgovyx (relugolix), as the first oral hormone therapy for the treatment of men with advanced prostate cancer. This new drug may eliminate the need to visit the clinic for treatment, helping patients with cancer avoid unnecessary exposure during the pandemic. Read More ›

Ayesha Azam, VP of Medical Affairs at the Patient Access Network Foundation, explains the different ways that this organization provides financial assistance and grants for nearly 70 different medical conditions, including cancers and rare diseases. Find out if you qualify for financial support. Read More ›

Plunging from nightmare to nightmare, Serena was diagnosed with breast cancer, while her 39-year-old husband, Robert, had a stroke, which claimed his speech and movement, leaving him “trapped in a thoroughly trashed body.” Paying the medical bills added to their struggles during the pandemic. Read More ›

Two oral health experts offer a thorough exploration of bone marrow transplants and how they relate to the mouth, with many tips for maintaining proper oral care during and after a transplant. Read More ›

Peter Smith painted most of his life, but his paintings gained a new importance and perspective after his multiple myeloma diagnosis. Read More ›

Dr. Garcia-Manero, an expert on myelodysplastic syndromes, discusses this group of disorders representing a misunderstood and often ignored type of blood cancer. He explains everything from risk factors to early symptoms and treatment options. Read More ›

In January 2021, the FDA approved a new indication for Xalkori (crizotinib), an oral ALK inhibitor, for the treatment of young patients who are diagnosed with relapsed or refractory systemic anaplastic large-cell lymphoma and ALK mutation. Xalkori was previously approved for metastatic lung cancer and ALK or ROS1 mutation. Read More ›

In December 2020, the FDA approved Xpovio (selinexor), for use in combination with the proteasome inhibitor Velcade (bortezomib) and the steroid dexamethasone, for the treatment of adults with multiple myeloma who have received at least 1 previous therapy. Xpovio was previously approved for several types of lymphoma. Read More ›